10/20/2013

FOLLOWING the meetings on 10/16/2013:

Please read and e-mail me your reaction

My comments on 8AM EST Google Hangout with ASI and Nestar

and

My Cocmment on 4PM EST Skype with Hlozek on ValveCure

From: jdpmdphd@gmail.com
To: AvivaLev-Ari@alum.berkeley.edu
Sent:Thu Oct 17 05:05:23 UTC 2013
Subject: Re: URGENT, URGENT, URGENT — >>>>>> REMINDER: TODAY at 4PM EST — SKYPE session with Edward Hlozek — you will join us on Skype — VALVE CURE

Good meetings!
You are excellent at connections and emphasizing value!

I have multiple procedures  and consults, so I can’t talk further today.

On Oct 16, 2013 7:56 AM, “Aviva Lev-Ari” <AvivaLev-Ari@alum.berkeley.edu> wrote:

1 we need to explore i-kNOw for funding of the engineering design
of the proof of concept with Ari Berger – $5 million

2 we need to SKYPE with the Product Engineering fellow on i-kNOw, given we reach an agreement on the new entity and the paertnership between you and me

3 we need to SKPE with Eric Hilman on the Business Plan to be need for i-kNOw, given we reach an agreement on the new entity and the paertnership between you and me

        4 we need to SKPE with Dr. Droutman and Mr. Ryan regarding i-kNOw,given we reach an agreement on the new entity and the paertnership between you and me and we decide to involve them in fund raising

#5
You and me need a SKYPE on Co-curation

Aviva Lev-Ari, PhD, RN

 

From: aviva.lev-ari@comcast.netTo: jdpmdphd@gmail.comSent:Thu Oct 17 05:41:21 UTC 2013, VALVE CUREThe meeting at 4PM was originally for us not for ValveCure, do you remember?

I was back my time scheduled with you.

Did you see all the points, in this e-Mail, each needs be answered by you.

Edward sent NDA, we need to propose TIME and Communication MEDiUM for your presentation to the Scientific Advisory Board.

I will get involved in actively identifying FUNDing for VALVECure ONLY if:

1. Product is modified with your FOUR additional Product Features
2. We are defined as Shareholders
3. Commission for Funding defined for my activity

I will get involved in product development for i-kNOw ONLY if:

1. Recognition by YOU of the following:
1.1 my guidance of your thought trail Leading to I-kNOw which is different from Wheelfly!!
1.2 my introduction to you of the following:
1.2.1 ASI, Inc
1.2.2 Eric Hilman for Business Plan and finance
1.2.3 Tal for Engineering Design
1.2.4 Golman and Berger for Funding, upon infusion of Capital

2. Product to have two front end options: one of nasal cannula, one of face inhalation small mask like N95

3. size of canisters minutirized, few other modification I wish to suggest to my design of two/three tubings converging into one with the sensor at the junction
4. As 2 above
5. As 3 above

Sent from Xfinity Connect Mobile Aviva Lev-Ari, PhD, RN

From: <aviva.lev-ari@comcast.net>
Date: Thu, 17 Oct 2013 06:23:30 +0000 (UTC)
—– Forwarded Message —--From: aviva.lev-ari@comcast.netTo: jdpmdphd@gmail.comSent:Thu Oct 17 06:22:30 UTC 2013Subject: Re: URGENT, URGENT, URGENT — >>>>>> REMINDER: TODAY at 4PM EST — SKYPE session with Edward Hlozek — you will join us on Skype — VALVE CURE

Do I need to apologize to you that because of me
1. I-kNOw was born
2. ValveCure functionality is to be augmented by 4 features
3. The concept of RF for Aorta Dissection was born, NOT in your mind otherwise, if not for me!!

Do I need to apologize to YOU that because of me – your BUSINESS in the log house on the Lake is NOW booming:

1. YOU are Content Consultant for Series A: Seven Volumes
(Volume Three, Four, Five are NOT your expertise, but mine – thus, my IP has been repatriated w/RELIEF)
2. I invented YOU as Co-Curator for 20 very fine articles in Volume Two, not existent in 1/2013
3. I made YOU Curator for Volume Six – came HANDY for ValveCure meeting
4. I made YOU Author, Curator, Editor for Volume Seven, came HANDY for your Presentation to the Scientific Advisory Board
5. I made you EDITOR for CVD 1,2,3 – to be considered by Thieme in Germany for HARD Copy, Three Volume Series, Anssi in Finland will Skype with US and the German Publisher in November
6. New venture, I-kNOw was born
7. Participation in Redefinition of ValveCure, thus, rationale to claim % in Venture Ownership

What is NOW my share in YOURS
1. MindShare
2. Future Net worth
3. Future Net Marginal Additional FAME that is made in Newton, MA and is NOT made in Bakersfield, CA or to put it straight, without me – could/would not to have come to fruition/fallen on your lap and bestowing YOU

YOU PUT AN END TO YOUR NEGATIVE EMOTION QUOTIENT! AND prevalent EMOTIONAL POVERTY in prominence

You do it at once
or
I part to do my own Rotations and Revolutions in orbits defined by your absence.

I will continue to be approached by the ilk of Lerner, Ryan, Droutman, Hlozek – venture to fetch one or more Cardiologists, MD, PhDs and move on with all my wares and my Journal with a price tag of $10 million, doing that without YOU.

To be or not to be !

 

10/15/2013

 

TOMORROW 10/16

#1

5AM PST (8 in the morn EST) – SKYPE with Lerner, Nestar (Israel) about the DESIGN of the Inhaled Nitric Oxide Device for HomeCare Market

 

#2

1PM PST (4PM EST) – Skype with Edward Hlozek – ValveCore

 

#3

 

Dr. Droutman and Mr. Mike Ryan are available to SKYPE with you on your OWN Patents NOT on ValveCore

I need to e-mail them WHEN you are available for SKYPE with them, After Hlozek ot Thu or Fri this week on on NEXT week

 

Please e-mail me confirmation #1,#2, time forr #3

10/2/2013

0. e-mail to Arlene Liguori <arlene.liguori@rcmt.com> on 10/8

Research & Development Consultant – R&D needs in developing covered stents (mesh covering).

0.1

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Date: Tue, 08 Oct 2013 12:52:19 -0400

To: Marcus W Feldman , Justin MDMEPhD

Cc: Abraham Meidan

Subject: 2001, 2003 Patents on Data Mining Algorithms for application in Probability based Medical Diagnosis Prediction

SHARING OUR LinkedIn Story – e-mail your input

I will share the DRAFT before I will submit it to LinkedIn to become one featured member profile in the press, on LinkedIn site, or in LinkedIn social media channels

Thank you again — I hope it will help our Venture

1.

Lerner wants to continue explorations of his Sensors – E-mail sent 10/6/2013

2.

Ari Berger will report good news after 10/17 back from Portugal

3.

RF for Mitral Valve – Clinical Trial design —

NDA sent to Larry Droutman 10/2 JDP, 10/8 ALA

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Date: Tue, 24 Sep 2013 15:15:34 -0400

To: <miker@capitalandmergers.com>

Cc: Justin MDMEPhD

Conversation: Client Seeking a Partnership for Expansion

Subject: Client Seeking a Partnership for Expansion

attn:

Michael T. Ryan

CEO

Healthcare Capital and Mergers

A Division of Worldwide Capital and Mergers, LLC

Mr. Ryan Hello,

Thank you for your LinkedIn In-mail of 9/18/2013, regarding your Client Seeking a Partnership for Expansion, and for reaching out to me.

Your e-mail has been shared with our Venture’s Cardiovascular Expert

Justin D. Pearlman MD, PhD, FACC

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Date: Fri, 27 Sep 2013 15:16:30 -0400
To: Justin MDMEPhD
Conversation: Your email to Mike Ryan re Client Non-Implantable Mitral Valve device
Subject: FW: Your email to Mike Ryan re Client Non-Implantable Mitral Valve device

From: Larry Droutman
Date: Fri, 27 Sep 2013 14:04:59 -0500
To: <AvivaLev-Ari@alum.berkeley.edu>
Cc: <miker@capitalandmergers.com>
Subject: Your email to Mike Ryan re Client Non-Implantable Mitral Valve device

Dear Dr. Lev-Ari,

I am replying to your email to Mike Ryan, CEO of Healthcare Capital & Mergers, in which you suggested a possible clinical trial collaboration after reviewing additional information about our client who is looking to commercialize a non-implantable device developed to shrink an enlarged mitral valve.

WE NEED TO IGN NON CONFIDENTIALITY AGREEMENT

4.

AHA Collaboration

From: “Westcoat, Matt”

Date: Thu, 26 Sep 2013 11:34:29 +0000

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Justin MDMEPhD

Conversation: Collaboration

Subject: RE: Collaboration

Hi Aviva

I have forwarded to the appropriate person on our team and they will reach out if there’s interest.

Thanks,

Matt

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Date: Wed, 25 Sep 2013 18:19:02 -0400

To: <Matt.Westcoat@wolterskluwer.com>

Cc: Justin MDMEPhD

Conversation: Collaboration

Subject: Collaboration

In reply to

Sent:Sun Sep 15 03:58:35 UTC 2013

Subject: Cardiology Recruitment Ad Opportunities – American Heart Association Medical Journals

I am interested to explore the following issues:

How can I use AHA Channels to

1. Advertise Nitric Oxide e-Book

2. Advertise forthcoming Cardiovascular Diseases, Volume 1,2,3

3. Find a Publisher buyer for Cardiac, Cardiovascular, Cardiac Medical Devices Research categories in

Http://pharmaceuticalintelligence.com

4. Publish in hardcopy Cardiovascular Diseases, Volume 1,2,3

A. Please connect me with the right Exec at American Heart Association, his employer

B.  is AHA connected to American College of Cardiology, European Cardiology Society, Chinese College of Cardiology

C. I a interested to work out an agreement of mutual ads in our Journal, theirs in our Journal Ours and Ours in AHA

5.

Melissa Meyers – Cardiologist Leads

From: Melissa Meyers <melissa.meyers@lakegroupmedia.com>
Date: Tue, 1 Oct 2013 20:28:48 +0000
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: “Stephen Williams, PhD” <sjwilliamspa@comcast.net>
Conversation: Inquiry: Cardiologist Leads
Subject: RE: Inquiry: Cardiologist Leads

Hi Aviva,

Hope this email finds you well. Sorry I was out of the office due to a family emergency.

As per your request mentioned below à

Only one of the membership lists that you are looking for is on the market and That is The list of American College of Cardiology membership list. Please see the rate card attached.

This list is available only for rental and only for direct mail (postal use). Each usage would need to be approved by ACC via submission of a sample mail piece.

You would not be able to use the file to see if any of the Cardiologists on the B2B file are members.

From: Melissa Meyers <melissa.meyers@lakegroupmedia.com>
Date: Wed, 25 Sep 2013 21:55:47 +0000
To: “avivalev-ari@alum.berkeley.edu” <avivalev-ari@alum.berkeley.edu>
Conversation: Inquiry: Cardiologist Leads
Subject: RE: Inquiry: Cardiologist Leads

Hi Aviva,

Nice to meet you and thank you for your inquiry. Your information was passed on to me by “Amber Watson” and I would be your point of contact from here on.

As per your request mentioned below à
     List of Cardiologists across USA: we have 26,283 Contacts with permission pass Emails.

Our pricing is based on 3 factors:
I.         Volume of contacts acquired.
II.        Number of Filters added to a given list.
III.      Any list purchased outside of the USA, then it becomes an International Listing and the pricing defers.
6.

CCO

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Date: Tue, 01 Oct 2013 18:32:04 -0400
To: Amy Goldman <agoldman@clinicaloptions.com>
Cc: “Stephen Williams, PhD” , Ritu , “Tilda Barliya, PhD” , Justin MDMEPhD , “Dr. Larry Bernstein” , Marcus W Feldman , “Dr. Vivek Lal”
Conversation: THANK YOU for CALLING to follow up with Aviva Lev-Ari, PhD, RN — Explorations in ONCOLOGY, GENOMICS, CARDIOVASCULAR
Subject: THANK YOU for CALLING to follow up with Aviva Lev-Ari, PhD, RN — Explorations in ONCOLOGY, GENOMICS, CARDIOVASCULAR

Dear Ms. Goldman,

Thank you for setting up the call this afternoon and for the exchange of information we had, which I found to be very productive.

Few points were mentioned, please forward this e-mail to the appropriate Executive at CCO.

POINT #2:

Cardiovascular Diseases — Number 1 Killer in the US

We have created Content in this domain as I specify below, I am expressing here my interest to explore avenues with CCO for the following goals:

Clinical Care Options (CCO), a pioneer and global leader in the development of medical education and online publishing, has created unique, innovative, interactive, multimedia educational programs and proprietary portal technologies for HIV, hepatitis, and hematology/oncology healthcare professionals since 2002 and is developing additional specialty portals.
In addition to its comprehensive specialty Web sites (http://clinicaloptions.com) that are now used in more than 200 countries, CCO has also created a remarkable new point-of-care technology platform and educational model called inPractice®: CCO’s own point-of-care textbook and comprehensive resource, underpinned by unique technology (http://inpractice.com).

2.1
Dr. Lev-Ari will launch the Cardiovascular Diseases (CVD) Discipline @ CCO with a focus on four Perspectives:

• CVD & Pharmaco-therapy
• CVD Genetics & Genomics
• CVD Regenerative Medicine and the Stem Cell Therapy Promise
• CVD & Medical Imaging for Disease Diagnosis and Guidance of Treatment

An overview of our Content Creation Process (CCP) is described in:

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation
http://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

Cardiovascular Diseases (CVD) Discipline will be a NEW point-of-care technology platform and educational model called inPractice®: CCO’s own point-of-care textbook and comprehensive resource, underpinned by unique technology (http://inpractice.com)

using the following Cardiovascular CONTENT created by the Team of Leaders in Pharmaceutical Business Intelligence, in the following e-Books:

2.1.1
Perspectives on Nitric Oxide in Disease Mechanisms
available on Kindle Store @ Amazon.com

http://www.amazon.com/dp/B00DINFFYC
PRLog site Press Release
http://www.prlog.org/12177251-leaders-in-pharmaceutical-business-intelligence-announces-the-first-book-of-their-biomedical-series.html

2.1.2
Cardiovascular Diseases: Causes, Risks and Management

Volume One

Causes of Cardiovascular Diseases
Justin D. Pearlman MD PhD MA FACC, Editor
http://pharmaceuticalintelligence.com/biomed-e-books/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/volume-one-causes-of-cardiovascular-diseases/

2.1.3
Cardiovascular Diseases: Causes, Risks and Management

Volume Two

Risks of Cardiovascular Diseases
Justin D. Pearlman MD ME PhD MA FACC, Editor
http://pharmaceuticalintelligence.com/biomed-e-books/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/cvd-2-risk-assessment-of-cardiovascular-diseases/

2.1.4
Cardiovascular Diseases: Causes, Risks and Management

Volume Three

Management of Cardiovascular Diseases
Justin D. Pearlman MD ME PhD MA FACC, Editor
http://pharmaceuticalintelligence.com/biomed-e-books/httppharmaceuticalintelligence-combiomed-e-bookscardiovascular-diseases-causes-risks-and-management/cvd-3-management-of-cardiovascular-diseases/

Our Team working on Cardiovascular Diseases (CVD)

Bios:

Aviva Lev-Ari, PhD, RN, BioMed e-Books Series – Editor-in-Chief
http://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/
http://pharmaceuticalintelligence.com/biomed-e-books/

Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor e-Book on Cardiovascular Diseases
http://pharmaceuticalintelligence.com/contributors-biographies/justin-d-pearlman-ab-md-me-phd-ma-facc-expert-author-writer-editor-e-book-on-cardiovascular-diseases/

Larry Bernstein, MD, FACP, Chief Scientific Officer, Member of the Board, Expert, Author, Writer
http://pharmaceuticalintelligence.com/contributors-biographies/larry-bernstein/

Vivek Lal, MBBS, MD, F.Cl.R. (Lt. Col – Retired), Expert, Author, Writer
http://pharmaceuticalintelligence.com/contributors-biographies/vivek-lal-mbbs-md-f-cl-r-lt-col-retired-expert-author-writer/